Clinical trial · Observational
The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases
The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases: A Pilot Study
NCT01180907CI-TRIAL-00007638completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to determine whether positron emission tomography using the new imaging agent 18F-FAC can be used for imaging cancer and/or inflammation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Inflammation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- patients with cancer
- label
- patients with autoimmune diseases
- label
- healthy subjects
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \> 18 years of age * women of childbearing potential will undergo a pregnancy test free of charge * patients with cancer or autoimmune diseases or healthy subjects
References
Publications (0)
Data not yet available
No reference posted for this study.